Our Team

Vensana's℠ team shares a passion for medical technology innovation and entrepreneurship. Our investment professionals and advisors are singularly focused on the sector, and we bring our experience, network and resources to bear at every stage of the company building process.

Justin Klein, MD, JD
Co-founder and Managing Partner

Justin Klein is a co-founder and Managing Partner at Vensana Capital. Justin was previously a partner at NEA, where he was a leader of the firm's medical technology investing practice.

Justin Klein, MD, JD, is a co-founder and Managing Partner at Vensana Capital, a leading venture capital and growth equity firm dedicated to medtech innovation. Justin was previously a partner and leader of the medical technology investing practice at NEA, one of the largest and most active venture capital firms in the world.  Justin also worked at the Duke University Health System where his experience included roles in strategy, finance and operations as Duke built one of the nation’s first integrated healthcare delivery systems. Justin currently or previously served on the board of directors of Apella, Cartiva (acquired), ChromaCode, Cleerly, Curate BioSciences, CV Ingenuity (acquired), Epix Therapeutics (acquired), Evident Vascular, FIRE1, Intact Vascular (acquired), Metavention, Personal Genome Diagnostics (acquired), PhaseBio Pharmaceuticals (IPO), Plexium, Relievant Medsystems (acquired), Senseonics (IPO), Topera (acquired), Ulthera (acquired), Vertiflex (acquired), Vesper Medical (acquired), and VytronUS (acquired). Justin currently serves as a member of the Board of Directors of the Medical Device Manufacturers Association and that of AdvaMed Accel, where he is the Vice Chair of the Investor Advisory Committee of AdvaMed's board. Justin graduated with an AB in Economics, a BS in Biological Anthropology & Anatomy, and a Minor in Chemistry from Duke University.  He also concurrently earned his MD from the Duke University School of Medicine and his JD from Harvard Law School.

Kirk Nielsen
co-founder and Managing Partner

Kirk Nielsen is a Managing Partner at Vensana Capital. Kirk co-founded Vensana as a Managing Director at Versant Ventures, where he led the firm's medtech practice.

Kirk Nielsen is a Managing Partner at Vensana Capital.  Kirk co-founded Vensana in early 2019 as a Managing Director at Versant Ventures, where he led the firm's medtech practice.  He joined Versant in 2006 from Medtronic, where he worked in sales & marketing in the company’s Cardiac Rhythm Management division.  Previously, he spent time at Fluidigm (a Versant portfolio company) and he also served as a consultant at Bain & Company, where he advised clients in healthcare, private equity, and other industries. Prior to his business career, Kirk was a professional hockey player. Kirk has led or co-led investments in numerous companies that have successfully exited, including Biotie Therapies, Cameron Health, CardiAQ, Ceterix Orthopedics, Lutonix, NeuWave Medical, Respicardia, Sequent Medical and Veran Medical, and he remains active with Alleviant Medical, CVRx (IPO), Inari Medical (IPO), Metavention, Moxe Health, and SpyGlass Pharma. Kirk also serves as a member of the Board of Directors of the National Venture Capital Association. Kirk graduated with a BA in Biology from Harvard College, where he won the John P. Reardon award as the school's top scholar-athlete, and he earned an MBA from Harvard Business School, where he was a Baker Scholar.

Amrinder Singh
Partner

Amrinder Singh is a Partner at Vensana Capital. Amrin was previously a Senior Investment Director at Medtronic Ventures and brings over a decade of investment and operating experience to Vensana.

Amrinder Singh is a Partner at Vensana Capital. Amrinder was previously a Senior Investment Director at Medtronic Ventures where he supported new investments in the medtech, diagnostics, and digital health spaces along with providing operational and board management support to portfolio companies. Prior to his investment career, Amrin led Business Development & Strategy for Medtronic’s remote monitoring and services businesses and was previously with the Corporate Strategy group. Before joining Medtronic, Amrin held product management and engineering positions at Thoratec Corporation. Amrin currently serves on the board of Nyra Medical. Amrin graduated from University of California, Davis in Biosystems Engineering and earned his MBA from Northwestern University, Kellogg School of Management.

Cynthia Yee
Partner

Cynthia Yee is a Partner at Vensana Capital. Cynthia brings nearly two decades of investing, operating, and public equities experience to Vensana.

Cynthia Yee is a Partner at Vensana Capital. Cynthia brings nearly two decades of investing, operating, and public equities experience to Vensana. Prior to joining Vensana, she served as a Principal at Windham Venture Partners, where she led the firm’s investments in multiple companies, including Cartiva Medical (acquired), ClarVista Medical (acquired), Personal Genome Diagnostics (acquired) and NeuSpera Medical.  She was previously an investor at NEA working across its medtech and healthcare services practices, and she spent time in business development and strategic marketing at Epix Therapeutics and medtech incubator D3DC. Cynthia began her career in public equities, covering medical devices at Piper Jaffray and biotechnology at Pacific Growth Equities. Cynthia currently serves on the board of directors of Evident Vascular and SpyGlass Pharma. She graduated from the University of California, Berkeley with a BA in Integrative Biology and a BS in Business Administration at the Haas School of Business.

Greg Banker
Partner

Greg Banker is a Partner at Vensana Capital. Greg brings over a decade of investing, operating and consulting experience.

Greg Banker is a Partner at Vensana Capital. Greg brings over a decade of investing, operating and consulting experience. Prior to joining Vensana, Greg served as Director of Strategic Market Development at Vertiflex, an interventional spine medical device company that was acquired by Boston Scientific in 2019. Greg's prior experience includes his work as an Associate Director at Navigant Consulting, where he advised medtech CEOs and boards of directors on over two dozen strategic market assessments across a range of sectors including cardiology, interventional pain, orthopedics, neurology, and robotic surgery. Greg currently serves on the board of Artelon. He graduated with a BS in Biology from the University of Wisconsin - Madison.

Mike Kramer
Partner

Mike Kramer is a Partner at Vensana Capital. Mike brings over 20 years of experience in operations, finance, and accounting to the Vensana team.

Mike Kramer is a Partner at Vensana Capital. Mike brings over 20 years of experience in operations, finance, and accounting to the Vensana team. Prior to joining Vensana in 2021, Mike was an Operating Partner at CRG LP, a leading provider of structured debt and equity capital for growth stage healthcare companies, where he advised on multiple medical technology company investments and worked directly with the boards of CRG’s portfolio companies. Previously, Mike has served as CFO or COO at private and public medical device companies including Endologix, TriVascular (IPO, acquired), and ATS Medical (IPO, acquired). In addition, he served as a manager in the assurance and advisory services practice at Ernst & Young LLP. Mike is a certified public accountant (inactive) and received his Bachelor of Accountancy from the University of North Dakota.

Bill Hoffman
Venture Partner

Bill Hoffman is a Venture Partner at Vensana Capital.  Bill currently serves as a member of the board of directors of Inari Medical, where he held the CEO role from 2015 until 2022.

Bill Hoffman is a Venture Partner at Vensana Capital.  Bill currently serves as a member of the board of directors of Inari Medical, where he held the CEO role from 2015 until 2022, leading the company through its initial public offering and helping to establish it as the global leader in the treatment of venous thromboembolism. He previously served as CEO at Visualase, a private company focused on MRI-guided laser ablation for the treatment of epilepsy and brain cancer, from 2008 until its acquisition by Medtronic in 2014.  Prior to this, Bill served as VP Sales at FoxHollow Technologies, which pioneered atherectomy to treat peripheral artery disease and was acquired by ev3 in 2007.  Bill received his BA in Economics from Dickinson College.

Steve Schwen
Partner and Chief Financial Officer

Steve Schwen is a Partner and Chief Financial Officer at Vensana Capital. Steve has over 25 years of finance and operations management experience within venture capital and private equity organizations.

Steve Schwen is a Partner and Chief Financial Officer at Vensana Capital.  Steve has over 25 years of finance and operations management experience within venture capital and private equity organizations.  Prior to joining Vensana, Steve served as a CFO Partner with Aduro Advisors, a venture capital fund administrator.  He was CFO of Split Rock Partners and its predecessor firm, St. Paul Venture Capital with responsibility for all areas of fund operations, finance, compliance, investor relations, information technology, and human resources.  Steve began his career at KPMG providing audit and consulting services to financial services companies.  He graduated with a BA in Business Administration – Accounting from the University of St. Thomas and is a licensed CPA (inactive).

Maggie Sullivan
Senior Operations Associate

Maggie Sullivan is a Senior Operations Associate at Vensana Capital. Maggie was previously an Associate at J.P. Morgan Private Bank, and she brings financial analysis, relationship management, and operations experience to Vensana.

Maggie Sullivan is a Senior Operations Associate at Vensana Capital.  Maggie’s responsibilities include investment process support, financial analysis, investor relations, and operations management.  Prior to joining Vensana, Maggie worked as an Associate at J.P. Morgan Private Bank, where she provided comprehensive wealth management support to clients with complex financial needs. Maggie graduated with a Bachelor of Business Administration and Certificate in Spanish Studies from the University of Wisconsin – Madison, and she is currently a CFA candidate. 

Kristie Fox
Executive Assistant / Office Manager

Kristie Fox is the Executive Assistant and Office Manager in our Vienna, VA office and brings over 20 years of experience as an EA.

Kristie Fox is the Executive Assistant and Office Manager in our Washington, D.C. office and brings over 20 years of experience as an EA.  Prior to joining Vensana, Kristie spent 12 years at NEA in various roles within their healthcare team, where she supported Justin Klein.  Preceding NEA, Kristie worked at Kleiner Perkins Caufield & Byers within their life sciences team. She graduated with a BA degree in Communication Studies from The University of Montana.

Neilly Newman
Executive Assistant / Office Manager

Neilly Newman is the Executive Assistant and Office Manager in our Minneapolis Office and brings over 20 years of experience as an EA.

Neilly Newman is the Executive Assistant and Office Manager in our Minneapolis office and brings over 20 years of experience as an EA.  Prior to joining Vensana, Neilly spent over 6 years at Versant Ventures, where she supported Kirk Nielsen. Preceding Versant, Neilly was an executive assistant at Polycom and Electronic Arts.  She graduated with a BS degree in Psychology from Santa Clara University.

Advisors

Our team of advisors is comprised of senior operating executives, entrepreneurs, and policy experts from across the medtech sector. Each of these advisors has served as a trusted partner to us or to our companies, often multiple times. They have helped shape the medtech industry and are committed to supporting our entrepreneurs as they build the next generation of great medtech companies.

Michael Ackermann, PhD

CEO, Presidio Medical
CEO, Oculeve

Todd Berg

CEO, Metavention
CEO, Torax Medical

Adam Berman

CEO, Alleviant Medical
CEO, TVA Medical

Brad Bolzon, PhD

Managing Director & Chairman, Versant Ventures

Jim Bullock

CEO, Atritech
CEO, Endocardial Solutions

Gene de Juan, MD

Vice Chairman/Founder, ForSight Labs
Professor of Ophthalmology, UCSF

Earl Fender

CEO Nalu Medical
CEO, VertiFlex
President, J&J DePuy Spine

Bill Hoffman

CEO, Inari Medical
CEO, Visualase

Kevin Hykes

CEO, CVRx
CEO, Bardy Diagnostics
CEO, Relievant Medsystems
CEO, Cameron Health

Malik Kahook, MD

Co-Founder, SpyGlass Pharma
Co-Founder, ClarVista Medical

Matt Likens

CEO, GT Medical Technologies
CEO, Ulthera

Angela MacFarlane

CEO, Voyant Biotherapeutics
CEO, ForSight Vision 4
CEO, ForSight Vision 5

Shawn McCormick

CFO, Aldevron
CFO, Tornier
COO, Lutonix

Salima Merani, PhD

Partner, Knobbe Martens

James Min, MD

CEO, Cleerly Health
Director, Dalio Institute of Cardiovascular Imaging

Rich Mott

Chairman, Relievant Medsystems
CEO, Kyphon

Stephen Oesterle, MD

Board Director, Baxter
Board Director, Paragon 28
SVP Medicine & Technology, Medtronic

Tim Patrick

CEO, Cartiva
CEO, Proxima Therapeutics

Bob Paulson

CEO, Sonex Health
CEO, VentureMed
CEO, NxThera

Bruce Shook

CEO, Vesper Medical
CEO, Intact Vascular
CEO, Neuronetics

Pete Sommerness

CEO, Enterra Medical
CEO, Respicardia
GM, Boston Sci EP

Roy Tanaka

President, J&J Biosense Webster

Art Taylor

CEO, Topera
COO & CFO, Kyphon

Leslie Trigg

CEO, Outset Medical
CCO, Lutonix

Dennis Wahr, MD

CEO, Nuvaira
CEO, Lutonix
CEO, Velocimed

Tom Wilder

CEO, Neuros Medical
CEO, Sequent Medical

Nadim Yared

CEO, CVRx
GM, Medtronic Navigation